Gemtuzumab Ozogamicin Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 4.5 mg
Reference Brands: Mylotarg (USA)
Category:
Oncology Cancer Care
Gemtuzumab Ozogamicin is available in Injection
and strengths such as 4.5 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Gemtuzumab Ozogamicin is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Gemtuzumab Ozogamicin can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Gemtuzumab ozogamicin is a humanized monoclonal antibody–drug conjugate used in the treatment of acute myelogenous leukemia. It is designed to target CD33-positive leukemic cells, allowing the attached cytotoxic agent to be delivered directly into malignant cells. This targeted mechanism helps concentrate the therapeutic effect on cancer cells while reducing exposure to healthy tissues, making it an important option in specific leukemia treatment protocols.
During therapy, gemtuzumab ozogamicin has been associated with transient elevations in serum liver enzymes, reflecting its impact on hepatic function. In some patients, treatment has also been linked to the development of acute sinusoidal obstruction syndrome, a serious liver-related complication that may occur during or after therapy. While this condition is not uncommon, its severity can vary, and in rare cases it may be life-threatening.
Due to these potential risks, gemtuzumab ozogamicin is administered under strict medical supervision with careful patient selection and monitoring of liver function. It is typically used in specialized oncology settings where the benefits of targeted leukemia therapy can be balanced against the known safety considerations.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing